Core Laboratories Inc.
CLB
$10.44
-$0.16-1.51%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 7,006.49% | -102.08% | -36.97% | 30.04% | 180.50% |
| Total Depreciation and Amortization | -1.26% | 1.45% | -0.33% | -2.49% | -1.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -134.83% | 3,529.17% | 89.78% | 65.98% | -149.60% |
| Change in Net Operating Assets | 172.62% | -119.00% | 1,159.23% | -110.78% | 185.86% |
| Cash from Operations | 109.05% | -67.69% | 57.40% | -23.61% | 210.05% |
| Capital Expenditure | -20.93% | 18.31% | -60.53% | 4.78% | 6.09% |
| Sale of Property, Plant, and Equipment | -21.46% | 53.37% | 503.01% | -36.06% | -64.92% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -25.18% | 15,505.00% | -99.05% | 6.80% | 145.76% |
| Cash from Investing | -312.95% | 121.69% | -624.85% | 28.53% | 58.54% |
| Total Debt Issued | -7.69% | 116.67% | -62.50% | 100.00% | -42.86% |
| Total Debt Repaid | 20.00% | 25.00% | 16.67% | -14.29% | -23.53% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -35.46% | 58.77% | -2,402.04% | -20.99% | -268.18% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 0.00% | 0.00% | 0.00% | 0.21% | -0.43% |
| Other Financing Activities | 11.11% | -- | 100.00% | -260.00% | 92.08% |
| Cash from Financing | 28.65% | 76.86% | -119.47% | 35.46% | -235.22% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 207.83% | 227.32% | -161.31% | 35.84% | 1,443.96% |